A case of Asthma with Behcet's disease: successful treatment with Omalizumab and its effects on recurrent aphthous lesions.
Conclusions: Here, for the first time, we introduce omalizumab treatment of a patient diagnosed with BD and the examination of the treatment for the clinical manifestations and the cytokines/coagulant protein levels. A significant improvement is observed in the patient's RAL following the initiation of omalizumab. There is strong evidence that the serum proinflammatory cytokines/coagulant factors could also play an important role in the relationship between RAL and IgE-dependent vascular autoinflammation.
PMID: 32605504 [PubMed - as supplied by publisher]
Source: Immunopharmacology and Immunotoxicology - Category: Allergy & Immunology Tags: Immunopharmacol Immunotoxicol Source Type: research
More News: Allergy & Immunology | Arthritis | Asthma | Behcet's Disease | Cough | Diabetes | Diabetes Mellitus | Emergency Medicine | Endocrinology | Genetics | Rheumatoid Arthritis | Rheumatology | Skin | Vasculitis | Xolair